Retatrutide, Eli Lilly’s investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, has been one of the most watched compounds in the metabolic research space. As Phase 3 trials continue to generate data, here’s what researchers are learning about this unique compound.
The Triple Agonist Mechanism
What makes retatrutide distinct is its mechanism of action. Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), retatrutide activates three receptor systems:
- GLP-1 receptor: Mediates effects on insulin secretion, glucagon suppression, and gastric emptying
- GIP receptor: Contributes to insulin sensitivity and may have independent effects on fat metabolism
- Glucagon receptor: This is the novel element - glucagon receptor activation increases energy expenditure and may promote fat oxidation
The combination of these three pathways is hypothesised to produce greater effects on metabolic parameters than single or dual agonists alone.
Phase 3 Trial Progress
Eli Lilly has been conducting multiple Phase 3 trials for retatrutide, including:
- TRIUMPH trials: Investigating retatrutide for weight management in adults with obesity or overweight
- Metabolic studies: Examining effects on liver fat, glycaemic control, and other metabolic parameters
- Cardiovascular outcomes: Long-term studies assessing cardiovascular safety and efficacy
The trials are enrolling thousands of participants across multiple countries, with Australia participating in several sites.
Key Findings So Far
While full Phase 3 data is still emerging, several findings have generated significant research interest:
- Weight management effects: Phase 2 data showed dose-dependent weight reduction, with the highest doses producing effects greater than those typically seen with GLP-1 only compounds.
- Liver fat reduction: Retatrutide has shown particular promise in reducing liver fat content, which has generated interest in its potential applications for metabolic-associated fatty liver disease (MAFLD).
- Glycaemic control: Improvements in HbA1c and fasting glucose have been observed, consistent with the compound’s incretin-based mechanism.
- Body composition: Some data suggests retatrutide may preferentially reduce fat mass while preserving lean mass, though this requires further investigation.
What Sets Retatrutide Apart
The research community has identified several factors that make retatrutide noteworthy:
- Triple mechanism: The addition of glucagon receptor activation is a novel approach that differentiates it from existing GLP-1 and GLP-1/GIP compounds.
- Liver effects: The pronounced effects on liver fat have opened new research avenues beyond traditional weight management.
- Dose-response relationship: The Phase 2 data showed a clear dose-response relationship, which helps inform dosing strategies for Phase 3.
Research Considerations
For those following retatrutide research, several points are worth noting:
- Phase 3 is ongoing: Full results from the large-scale Phase 3 trials are still being generated and will be published over the coming years.
- Regulatory timeline: TGA approval in Australia would follow completion of Phase 3 trials and regulatory submission, which is likely still some time away.
- Mechanism research: The triple agonist mechanism is still being characterised, and ongoing research is elucidating the relative contributions of each receptor pathway.
For more on retatrutide’s mechanism and research context, see our retatrutide overview. Join the discussion in our Telegram community.
Looking Ahead
Retatrutide represents a significant step in the evolution of incretin-based compounds. As Phase 3 data matures, researchers will gain a clearer picture of its efficacy, safety profile, and potential role in the metabolic research landscape.
The compound’s triple agonist mechanism also opens possibilities for combination approaches and next-generation compounds that build on this multi-receptor strategy.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.